Biomarker ID | 92 |
PMID | 15645116 |
Year | 2005 |
Biomarker | LY96 (lymphocyte antigen 96) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in PCa (2.4 fold ) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon,Endogenous Toll-like receptor signaling,TRAF6-mediated induction of TAK1 complex,Interleukin-6 regulation of target genes,Pathogenic Escherichia coli infection |
Experiment | Malignant Vs Benign Tissue |
Type of Biomarker | Diagnostic |
Cohort | Samples were collected from 33 patients. 52 specimens were obtained, out of which 19 were paired malignant and benign, 29 were primary tumors and 4 benign tissue samples |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | Microarray Analysis |
Clinical | No |
Remarks | Upon analysis, 51 genes were found which were differentially expressed. 30 top genes were taken on the basis of there t-test scores and leave one out cross validation was performed with Fischer's Linear Discrimant and 90.3% accuracy was achieved while discriminating between Tumor (T) And Benign (B) Samples |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | LY96 |